GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

The Centers for Medicare & Medicaid Services (CMS) has said it will announce the next 15 drugs in scope for the second round ...

The GSK share price is nearly 10% off its 52-week high, and this Fool is keen to take a closer look. Could it be a stock for ...

GSK-3739937 is commercialized by GSK, with a leading Phase I program in Human Immunodeficiency Virus (HIV) Infections (AIDS).

In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

GSK’s (LSE: GSK) share price is 9% down from its 15 May 12-month traded high of £18.19. This compounds the stock’s already extreme undervaluation against its competitors apparent to me beforehand.

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...

GlobalData uses proprietary data and analytics to provide a complete picture of GSK -3943104A’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here. The revenue for GSK -3943104A is ...